# Omalizumab

## Xolair inj 150mg/1.2mL

##### 臨採

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | IXOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 適應症     | --Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 用法用量   | Allergic asthma: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. Chronic spontaneous urticaria(CSU): Usual dose: 150 or 300 mg every 4 weeks. Dosing for this indication is not dependent on serum IgE (free or total) level or body weight.                                                                                                                                                                                                                                                                                                                                                        |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 禁忌       | Hypersensitivity reaction to omalizumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 副作用     | >10%: Central nervous system: Headache (6% to 12%) 1% to 10%: Cardiovascular: Peripheral edema (>2%) Central nervous system: Anxiety (>2%), migraine (>2%) Dermatologic: Alopecia (>2%) Gastrointestinal: Toothache (>2%) Genitourinary: Urinary tract infection (>2%) Infection: Fungal infection (>2%) Local: Injection site reaction (3%) Neuromuscular & skeletal: Arthralgia (3%), limb pain (>2%), musculoskeletal pain (>2%), myalgia (>2%) Respiratory: Nasopharyngitis (9%), sinusitis (5%), upper respiratory tract infection (3%), asthma (>2%), oropharyngeal pain (>2%), sinus headache (>2%), cough (2%), viral upper respiratory tract infection (<2%) Miscellaneous: Fever (>2%) All indications: <1% (Limited to important or life-threatening): Alopecia, anaphylaxis, antibody development, arthritis, chest tightness, Churg-Strauss syndrome, lymphadenopathy, malignant neoplasm, pulmonary hypertension, syncope, thrombocytopenia, transient ischemic attacks |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

